Sei Investments Co. Decreases Stake in Natera, Inc. (NASDAQ:NTRA)

Sei Investments Co. trimmed its stake in shares of Natera, Inc. (NASDAQ:NTRA - Free Report) by 3.6% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 293,009 shares of the medical research company's stock after selling 10,962 shares during the period. Sei Investments Co. owned about 0.22% of Natera worth $46,383,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in NTRA. Quantbot Technologies LP purchased a new position in Natera in the fourth quarter valued at about $878,000. Semanteon Capital Management LP boosted its stake in Natera by 25.6% during the 4th quarter. Semanteon Capital Management LP now owns 9,027 shares of the medical research company's stock valued at $1,429,000 after purchasing an additional 1,840 shares in the last quarter. Teacher Retirement System of Texas boosted its holdings in Natera by 37.9% during the fourth quarter. Teacher Retirement System of Texas now owns 43,693 shares of the medical research company's stock worth $6,917,000 after buying an additional 11,999 shares in the last quarter. Nikko Asset Management Americas Inc. increased its position in shares of Natera by 10.3% in the fourth quarter. Nikko Asset Management Americas Inc. now owns 740,837 shares of the medical research company's stock worth $117,274,000 after acquiring an additional 69,455 shares in the last quarter. Finally, Twin Tree Management LP grew its position in Natera by 223.7% during the fourth quarter. Twin Tree Management LP now owns 17,321 shares of the medical research company's stock valued at $2,742,000 after purchasing an additional 31,321 shares in the last quarter. Institutional investors and hedge funds own 99.90% of the company's stock.

Remove Ads

Insider Buying and Selling at Natera

In related news, insider Solomon Moshkevich sold 24,861 shares of the business's stock in a transaction that occurred on Wednesday, January 22nd. The stock was sold at an average price of $164.97, for a total value of $4,101,319.17. Following the completion of the sale, the insider now owns 140,684 shares in the company, valued at approximately $23,208,639.48. The trade was a 15.02 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Steven Leonard Chapman sold 87,272 shares of the company's stock in a transaction on Wednesday, March 5th. The stock was sold at an average price of $143.40, for a total value of $12,514,804.80. Following the sale, the chief executive officer now owns 203,354 shares of the company's stock, valued at $29,160,963.60. This trade represents a 30.03 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 306,797 shares of company stock worth $48,940,883. 7.60% of the stock is owned by corporate insiders.

Natera Stock Performance

Natera stock traded down $4.36 during trading on Friday, hitting $143.94. The stock had a trading volume of 1,258,459 shares, compared to its average volume of 1,364,577. The stock has a market cap of $19.46 billion, a price-to-earnings ratio of -81.78 and a beta of 1.80. The company has a quick ratio of 4.23, a current ratio of 4.39 and a debt-to-equity ratio of 0.33. The stock's 50 day moving average is $159.60 and its two-hundred day moving average is $150.72. Natera, Inc. has a 1 year low of $83.13 and a 1 year high of $183.00.

Natera (NASDAQ:NTRA - Get Free Report) last announced its earnings results on Thursday, February 27th. The medical research company reported ($0.41) earnings per share for the quarter, topping analysts' consensus estimates of ($0.42) by $0.01. The business had revenue of $476.10 million for the quarter, compared to analyst estimates of $447.91 million. Natera had a negative return on equity of 26.23% and a negative net margin of 14.01%. As a group, analysts predict that Natera, Inc. will post -1.49 EPS for the current year.

Analysts Set New Price Targets

A number of research firms have issued reports on NTRA. Barclays began coverage on shares of Natera in a report on Thursday, January 23rd. They set an "overweight" rating and a $200.00 price target for the company. BTIG Research reiterated a "buy" rating on shares of Natera in a research report on Friday, February 28th. Guggenheim lifted their price objective on Natera from $170.00 to $200.00 and gave the company a "buy" rating in a report on Friday, January 17th. Piper Sandler upped their target price on shares of Natera from $200.00 to $205.00 and gave the stock an "overweight" rating in a report on Tuesday, March 4th. Finally, The Goldman Sachs Group increased their target price on shares of Natera from $160.00 to $190.00 and gave the stock a "buy" rating in a research report on Tuesday, January 28th. One research analyst has rated the stock with a hold rating and sixteen have issued a buy rating to the company's stock. Based on data from MarketBeat, Natera presently has a consensus rating of "Moderate Buy" and an average target price of $178.12.

Natera Company Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.